Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$1.1 - $2.09 $105 - $200
-96 Reduced 57.14%
72 $0
Q2 2023

Aug 09, 2023

BUY
$0.89 - $3.33 $149 - $559
168 New
168 $0

Others Institutions Holding INKT

About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $23M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.